Tesamorelin (10 mg) · Ipamorelin (3 mg) (Blend)

Growth hormone–releasing hormone (GHRH) is a 44-residue hypothalamic peptide that engages the GHRH receptor on pituitary somatotroph cells and participates in somatotropic-axis research. Native GHRH(1-44) is rapidly inactivated in plasma by dipeptidyl peptidase-IV, which cleaves the N-terminal Tyr-Ala dipeptide and limits its utility as a research reference compound. The development of stabilized GHRH analogs was driven by interest in molecules that preserve receptor engagement while resisting enzymatic deactivation.

Tesamorelin was developed as a synthetic GHRH(1-44) analog with a trans-3-hexenoyl moiety attached to the N-terminal tyrosine. This minimal modification confers resistance to dipeptidyl peptidase-IV cleavage while preserving the native amino acid sequence and receptor-binding pharmacophore, enabling extended plasma residency in laboratory research studies.

This structural design has made tesamorelin a widely studied reference compound for laboratory investigations of GHRH-receptor signaling, somatotropic-axis pulsatility, and downstream IGF-1 pathway dynamics. Research interest spans pituitary research models, hepatic lipid-metabolism research, adipose-tissue research models, and comparative pharmacology with other GHRH analogs and growth-hormone-releasing secretagogues.

The growth-hormone secretagogue receptor (GHS-R1a) was identified as the endogenous receptor for ghrelin, a 28-amino-acid acylated peptide involved in somatotropic-axis signaling and metabolic research. Early non-selective GHS research peptides (GHRP-6, GHRP-2, hexarelin) engaged GHS-R1a but also produced collateral activity at other endocrine pathways, limiting their utility as receptor-selective research tools.

Ipamorelin was developed by Novo Nordisk researchers as a five-residue scaffold designed to selectively engage GHS-R1a while minimizing collateral receptor activity. Structural studies and receptor-binding research established the pentapeptide as a high-affinity, high-selectivity GHS-R agonist suitable for laboratory investigation of receptor-mediated signaling.

This positioning at the intersection of ghrelin-receptor signaling research, selective GPCR pharmacology, and somatotropic-axis research models has made Ipamorelin a peptide of considerable interest in laboratory investigations of GHS-R1a biology and downstream growth-hormone-pathway dynamics.

1. GHRH-Receptor Engagement

Tesamorelin interacts with the GHRH receptor, a class B G-protein-coupled receptor expressed on pituitary somatotroph cells. Research models indicate that this engagement modulates Gαs-coupled signaling at the GHRH receptor, producing intracellular responses that are comparable to native GHRH(1-44) in laboratory side-by-side studies.

2. Modulation of Cyclic AMP and Pulsatile Growth Hormone Release

Upon receptor binding, tesamorelin engages adenylyl cyclase activity and modulates intracellular cyclic AMP accumulation in somatotroph research models. Downstream, this is associated with protein kinase A activation and pulsatile release of growth hormone from pituitary storage granules, both of which are extensively studied in somatotropic-axis research.

3. Resistance to Dipeptidyl Peptidase-IV

Laboratory research studies have characterized tesamorelin's trans-3-hexenoyl modification as conferring resistance to dipeptidyl peptidase-IV cleavage at the N-terminal Tyr-Ala dipeptide. This enzymatic stability is an active area of structure–activity research and is investigated as a contributor to extended plasma residency in research models relative to native GHRH(1-44).

4. Downstream IGF-1 Pathway Dynamics

Pulsatile growth hormone release in research models engages hepatic growth hormone receptors and modulates insulin-like growth factor-1 (IGF-1) gene expression and secretion. This downstream signaling cascade is investigated in lipid-metabolism research, hepatic-pathway research, and comparative pharmacology research with other somatotropic-axis modulators.

Research Applications

Conclusion

Tesamorelin represents a structurally engineered stabilized GHRH(1-44) analog that has become a central reference compound in GHRH-receptor signaling research. Its combination of preserved native sequence, N-terminal trans-3-hexenoyl modification, and resistance to dipeptidyl peptidase-IV cleavage makes it a valuable investigational laboratory peptide for studying class B G-protein-coupled receptor pharmacology and somatotropic-axis research models.

1. Selective GHS-R1a Engagement

Ipamorelin binds the growth-hormone secretagogue receptor (GHS-R1a, the ghrelin receptor), a Gq-coupled class A GPCR expressed on anterior-pituitary somatotrophs and selected peripheral tissues. Receptor engagement activates phospholipase-C, generates inositol-1,4,5-trisphosphate, and mobilizes intracellular calcium in laboratory research models.

2. Ghrelin-Receptor Signaling Research

Through GHS-R1a engagement, Ipamorelin is investigated as a probe for ghrelin-receptor-coupled signaling, including PLC/IP3/Ca2+ mobilization, MAPK pathway activation, and downstream transcriptional research in somatotroph cellular models.

3. Selectivity Profile in Receptor Research

Receptor-binding studies have characterized Ipamorelin as engaging GHS-R1a with minimal activity at adjacent endocrine receptor pathways. In laboratory research models, this selectivity is associated with absence of appreciable ACTH, cortisol, prolactin, or aldosterone receptor signaling, distinguishing it from earlier non-selective GHS research peptides.

4. Somatotropic-Axis Research Models

Ipamorelin is investigated alongside GHRH-receptor agonists (e.g., Sermorelin, CJC-1295, Tesamorelin) to study receptor-coupled signaling interactions between the GHS-R1a and GHRH-R pathways in controlled laboratory research.

Research Applications

Conclusion

Ipamorelin represents a structurally defined pentapeptide research compound that selectively engages the GHS-R1a (ghrelin) receptor. By providing high receptor selectivity within the somatotropic-axis research framework, it serves as a useful tool compound for examining ghrelin-receptor signaling research, selective GPCR pharmacology, and downstream growth-hormone-pathway dynamics in controlled laboratory models.